Explore Our Biomarker Menu

Biomarker:

IRE-1α (total)

Biological or Clinical Significance:

Inositol-requiring enzyme-1α (IRE-1α) is an endoplasmic reticulum (ER) transmembrane protein that mediates one of the three arms of unfolded protein response (UPR) adaptation to ER stressors. In response to recognition of misfolded proteins in the ER lumen, IRE-1α oligomerizes to activate its cytoplasmic kinase and endoribonuclease domains, which initiate cleavage of the mRNA encoding the transcription factor XBP-1 (x-box binding protein 1), an effector that drives the transcription of cytoprotective genes.1 IRE-1α can either return to an inactive state upon resolution of ER stress or enter a refractive state in which it no longer responds to unresolved ER stress after prolonged activation, limiting the cytoprotective duration of the UPR.2 Increasing evidence suggests that ER stress and IRE-1α are associated with adverse conditions such as diabetes, cancer, muscle degeneration, and neurodegenerative, bipolar, liver, cardiac, and autoimmune diseases.

References:

  • “Total IRE-1 Kit.” MSD Cell Signaling Pathway Assays (2013): n. pag. MESO SCALE. Meso Scale Diagnostics, LLC. Web. 21 Apr. 2016.

Analyte:

IRE-1α (total)

Matrix:

Status:

Experienced Running

Sensitivity-LLOQ:

Sensitivity-ULOQ:

platform

MSD-ECL

Required Sample Volume

Disease State:

MSD Panel:

Speak To A Scientist





    I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.

    Immunogenicity

    Learn why BioAgilytix is a world-leading authority on immunogenicity studies related to ADA, NAb assay development and validation, isotyping, and more.

    Case Studies

    Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.